Drug major Lupin on Tuesday posted a 35.11 per cent dip in
its consolidated net profit at Rs 408.8 crore for the second quarter ended
September 30, mainly on account of slowdown in product approvals in the US.
The company had posted a net profit of Rs 630 crore during
the same period of the previous fiscal.
Net sales of the company, however, rose to Rs 3,178.3 crore
during the second quarter compared with Rs 3,116.8 crore during the same period
of previous fiscal, Lupin said in a statement.
"Slowdown in approvals in the US and a lack of material
launches continued to dampen growth. We continue to invest in research and
remain upbeat on the pace of approvals and launches to pick up by the fourth
quarter," Lupin Ltd Managing Director Nilesh Gupta said.
The company's board, which met today, appointed Ramesh
Swaminathan Chief Financial Officer as an additional director and Jean-Luc
Belingard as an independent director of the company for a period of five years
effective October 27, subject to shareholders approval.
The company said its US sales stood at $174 million during
the second quarter as against USD 202 million in second quarter of the previous
fiscal.
During the second quarter, its India formulations business
grew by 9.4 per cent, recording sales of Rs 873.8 crore during the second
quarter as against Rs 799 crore during the same period of 2014-15.
Lupin's Japanese business posted net sales of Rs 323.4 crore
during the second quarter, as against Rs 345.9 crore in the same period of
previous fiscal.
The company's South African subsidiary, Pharma Dynamics
achieved sales of Rs 99.8 crore in second quarter compared with Rs 105.7 crore
last year.
The Mumbai-based firm's active pharmaceutical ingredients
(API) sales grew by 1.1 per cent to Rs 321.9 crore during the second quarter as
against Rs 318.3 crore during the same period of 2014-15.